HeartSine Wins Prestigious Management Award

HeartSine, the developer and manufacturer of life-saving AED units, won two prestigious awards for management in 2014.

“It’s a great honor for our highly experienced, hard-working management team to be recognized by such a prestigious organization–especially for our international success,” says Declan O’Mahoney, CEO of HeartSine Technologies. “Our global expansion is a direct result of the team’s commitment to excellence, innovation and quality.”

Annuvia is a proud partner of HeartSine, acting as the West Coast Premiere Partner, responsible for managing sales in the western 8 states. If you’re interested in learning more about partnership opportunities for your AED sales business or if you’re interested in learning more about HeartSine AEDs, you’re at the right place. Give us a call to see if we can help! (866) 364-7940

Share

Screening for Young Athletes: Is it Worth the Cost?

According to a new study, reported here, 7 out of 5000 school-aged athletes found serious heart abnormalities due to school-sponsored screening efforts. Screening programs have increased in recent years, in an attempt to “find” possible sudden cardiac arrest patients. There is a debate in the medical community as to whether screening programs are worth the investment. Costly equipment, time, and expert review can add up, making screening campaigns costly.

Depending on the condition identified, treatment options might be limited. What is undeniable, however, is that an AED unit will provide the best level of protection for those who are and are not diagnosed with a cardiac abnormality.

Where do you come in on the issue? Are screening programs worth the risk or are funds better spent on other programs, like saturating communities with AED units?

Share

Annuvia Medical Director First in Manhattan to Implant New Device

Nicholas Skipitaris, MD, director of electrophysiology at Lenox Hill Hospital is first in Manhattan to implant a new insertable cardiac monitor, the smallest cardiac monitoring device currently available.

Cardiac Implant

Dr. Skipitaris implanted the innovative cardiac monitor in a 34-year old Manhattan woman. The device is approximately the size of a thick matchstick, making it more than 80 percent smaller than other ICMs. The device is used for patients who experience symptoms such as dizziness, palpitations, fainting and chest pain that may suggest a cardiac arrhythmia, as well as for those at an increased risk for cardiac arrhythmias.

As reported on the Lenox Hill Hospital website: “The LINQ ICM is a truly innovative monitoring device and a dramatic improvement over previous generations of this apparatus, which were cumbersome, required up to 30 minutes to implant, left a visible scar and did not transmit data,” said Dr. Skipitaris. “This device brings together the best of technology and science allowing us to treat our patients more efficiently and without interrupting their daily life.”

In addition to providing life-saving solutions to his patients and partaking in innovative surgeries, Dr. Skipitaris serves as one of Annuvia’s Medical Directors, overseeing AED programs across the country.

Share

WordPress Themes